United States Molecular Diagnostics Market Report by Technology, Application, Product, End User, States and Company Analysis 2026-2034

United States Molecular Diagnostics Market Size & Forecast 2026-2034

The molecular diagnostics industry of the United States is expected to grow at a compound annual growth rate of 6.22% from US$ 5.21 billion in 2025 to US$ 8.96 billion by 2034. Factors contributing to this growth include the need for early disease detection, the prevalence of infectious and genetic diseases, and the improvement of PCR and sequencing techniques, along with the applications of molecular diagnostics in cancer research and personalized medicine.

United States Molecular Diagnostics Market Outlooks

Molecular diagnostics is a medical testing field focused on the analysis of biological markers in the genome and proteome. This involves methods such as PCR, Next Generation Sequencing, and nucleic acid amplification. This helps in early detection and management of diseases. This field of medical testing has been gaining much popularity in the United States. This is because of the accuracy, speed, and precision of medical tests.

In addition, the prevalence of chronic and infectious diseases, coupled with an increase in awareness of early detection of diseases, has led to an increase in the adoption of molecular diagnostics. The country also has a high level of healthcare infrastructure. This includes a high level of R&D activities and a presence of leading biotech companies. This has led to an increase in the use of molecular diagnostics in medical testing. In addition, the emergence of the Covid-19 pandemic has led to an increase in the acceptance of molecular diagnostics. This has led to an increase in the use of molecular diagnostics in medical testing. Hence, it can be clearly understood that molecular diagnostics plays a vital role in the transformation of medical testing in the United States.

Growth Drivers of the United States Molecular Diagnostics Market

Rising Prevalence of Chronic and Infectious Diseases

Every year, 23 million Americans consult a doctor or a medical clinic for the treatment of infections. One of the major factors contributing to the growth of the United States’ molecular diagnostics market is the rise in the incidence of chronic and infectious diseases. Cancer, diabetes, cardiovascular diseases, and infectious diseases such as influenza and viral diseases need to be diagnosed in an early stage to treat them properly. With the use of molecular diagnostics, diseases can be detected in an early stage or even before the appearance of severe symptoms. This helps in providing better healthcare outcomes and minimizing healthcare expenditure in the long run. In addition, the growing geriatric population in the United States is more likely to develop diseases, which again contributes to the growth of the United States’ molecular diagnostics market. This has led healthcare providers to use molecular diagnostic tests in their day-to-day practice.

Advancements in Diagnostic Technologies

Another significant factor contributing to the growth of the molecular diagnostics market in the United States is technological innovation. There have been many advancements in technologies such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and microarray analysis. These advancements have made it possible to detect multiple pathogens or genetic markers at a faster rate. For example, it has become possible to detect multiple pathogens simultaneously. Automation of these technologies has also made it possible to connect them with digital technologies, thereby reducing the time taken for tests. Additionally, it has become possible to carry out molecular diagnostics at home using point-of-care molecular diagnostic devices. This has been particularly helpful in managing outbreaks of infectious diseases. There has been significant investment in research and development activities in this field, with both governments and private players investing in it. Jan 2026, Insight Molecular Diagnostics Inc. announced a year-end business update related to its commercialization efforts, its clinical trial for its GraftAssureDx™ test kit, its planned submission for in vitro diagnostic device clearance to the United States Food & Drug Administration (FDA), as well as its future submission efforts and registry trial progress for 2026.

Growing Adoption of Personalized Medicine

The growing trend of personalized medicine is a significant contributor to the increased demand for molecular diagnostics in the US. Personalized medicine is a medical approach that is focused on the development of treatment plans according to the genetic makeup, lifestyle, and unique characteristics of the individual. Molecular diagnostics is a critical component in the development of personalized medicine since the genetic makeup of the individual determines the course of the disease. In the treatment of cancer, for example, the best course of action is determined using molecular diagnostics. Not only is the treatment effective, but the side effects are also reduced. The growing use of companion diagnostics, which are developed alongside the drug, is a significant contributor to the increased use of molecular diagnostics. In addition, the growing demand for precise medicine among patients is a significant contributor to the increased demand for these diagnostic tools. Therefore, personalized medicine is a significant contributor to the increased demand for molecular diagnostics. FEB 2026, The U.S. Food and Drug Administration has issued draft guidance for sponsors who wish to pursue full approval for targeted individualized therapies based upon substantial evidence of effectiveness and safety where randomized controlled studies are not possible due to small patient populations.

Challenges of the United States Molecular Diagnostics Market

High Cost of Molecular Diagnostic Tests

Despite all the benefits associated with using molecular diagnostic tests, one of the challenges associated with them in terms of market penetration in the United States market relates to their high cost. The use of advanced technologies in conducting tests such as next-generation sequencing and special PCR tests involves a high level of expenditure in terms of equipment and personnel. Although reimbursement of costs by insurance companies has improved in recent years, it still varies in some cases. This creates a financial dilemma for healthcare providers and patients. In addition, the cost of upgrading equipment used in conducting tests is a major financial challenge to laboratories. This challenge may impact the rate of adoption of tests, especially those that are newly developed.

Regulatory and Compliance Challenges

The US molecular diagnostics market is heavily regulated, which can sometimes become a hindrance for players in this market. There are several government organizations that regulate this market, like the FDA, which ensures that diagnostic tests are approved through rigorous tests to prove their safety, accuracy, and reliability. Though this is necessary to uphold the quality of diagnostic tests, it can sometimes become a hindrance for companies to introduce their products in the market in a timely fashion, as this can cause delays in their development process. Furthermore, with changing government regulations, like those for LDTs, this market is also uncertain for players in this field. Smaller companies can find it difficult to comply with government regulations, which is another challenge for this market.

United States In Situ Hybridization Market

The United States market for in situ hybridization (ISH) is a growing market, with this technique playing a crucial role in the detection and localization of specific nucleic acid sequences within tissue samples. This technique is commonly applied in cancer diagnostics, especially for identifying gene amplifications and chromosomal abnormalities. The prevalence of cancer and the need for precise diagnostic tools are driving the growth of this market. With technological advancements, this technique has become more sensitive and accurate, with techniques such as fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH) becoming very reliable tools. Furthermore, this technique has been integrated with digital pathology and imaging systems, making it more efficient for diagnostics. Although this technique is more expensive and complex, it plays a crucial role in modern molecular diagnostics, especially in cancer diagnostics.

United States Mass Spectrometry Market

The United States mass spectrometry market is growing, driven by its wide applications in clinical diagnostics, drug development, and biomarker research. Mass spectrometry is used for accurate detection and quantification of biomolecules, which is useful in proteomics, metabolomics, and toxicology studies. The increasing demand for advanced analytical technologies in personalized medicine and drug development is a key driver for market growth. Technological improvements, such as high-resolution instruments, have improved accuracy, speed, and efficiency. In addition, funding for life sciences research, combined with the presence of prominent biotechnology/pharmaceutical companies, is fueling growth. Clinical laboratories are increasingly adopting mass spectrometry for diagnostic purposes, especially for detecting metabolic disorders and infectious diseases. However, high costs of instruments and trained professionals are limiting factors.

United States Molecular Diagnostics Pharmacogenomics Market

The United States market for molecular diagnostics in the field of pharmacogenomics is on the rise, especially with the move towards a more personalized approach to medicine. Pharmacogenomics is a field that seeks to understand the genetic makeup of a patient and how this impacts their drug response. This is a key area for the application of molecular diagnostics, especially in the treatment of diseases such as cancer, cardiovascular diseases, and mental health disorders. The move is expected to gain traction as the importance of a personalized approach to medicine is realized. More and more healthcare providers and patients are becoming aware of the advantages that come with a personalized approach. The rise in the incidence of chronic diseases is also expected to contribute to the growth of the market. Pharmaceutical companies are now embracing the use of pharmacogenomic testing in their drug development programs. Companion diagnostics are on the rise. However, the market faces the challenge of regulatory hurdles and the issue of costs.

United States Oncology Molecular Diagnostics Market

The United States oncology molecular diagnostics market is one of the fastest-growing segments in the diagnostics market. The growth is mainly driven by the increasing prevalence of cancer cases and the need for early detection and accurate diagnostic tests for cancer treatment. Molecular diagnostics is significantly important in detecting cancer-specific genetic mutations to treat cancer effectively using targeted therapies. Molecular diagnostic tests, such as next-generation sequencing and polymerase chain reaction, are commonly used for cancer profiling and tracking cancer progression. The use of liquid biopsy, which is a non-invasive diagnostic procedure, is also changing cancer diagnostics in this market. Strong research and development activities, along with collaborations between biotechnology companies and healthcare institutions, are also fueling growth in this market. Furthermore, awareness about personalized cancer treatment is also creating a positive impact on this market, even though high costs are a concern in this market segment.

United States Molecular Diagnostics Hospitals Market

The United States molecular diagnostics hospitals market is witnessing growth as hospitals increasingly incorporate advanced technologies for patient care. Hospitals are a significant segment of the United States molecular diagnostics market due to the high volume of tests performed. Diagnostic tests are essential for patient care, as timely and accurate results are crucial for making timely decisions. Molecular diagnostics plays a significant role in hospitals for detecting infectious diseases, cancer, and genetic disorders. It facilitates timely and effective treatment for such patients. The implementation of automated systems has significantly contributed to efficiency in laboratories. The trend towards precision medicine and personalized approaches to patient care also contributes to hospital demand for advanced molecular diagnostics technologies. Government initiatives, positive reimbursement policies, and improvements in healthcare infrastructure are also contributing to growth. However, factors such as implementation costs and skilled personnel are a few challenges that need to be considered. Despite such factors, hospitals are a significant driver for growth.

Washington Molecular Diagnostics Market

The Washington molecular diagnostics market is growing at a steady rate due to the presence of a strong base of research organizations, biotech companies, and healthcare facilities. The state is benefiting from a well-developed life science industry, especially in cities like Seattle. There is a growing need for early disease detection, especially for cancer and infectious diseases. This is resulting in the increased adoption of molecular diagnostics technologies. Collaborations between academia and the government in funding biomedical research are also supporting the growth of the molecular diagnostics market in Washington. The use of advanced technologies like next-generation sequencing and digital diagnostics is also a major contributor. The focus on precision medicine and personalized healthcare is encouraging hospitals and healthcare facilities to invest in advanced technologies. However, the high cost and regulatory hurdles are some of the challenges facing the market. Nevertheless, the Washington market is a significant contributor to the growth of the regional molecular diagnostics market in the USA.

New Jersey Molecular Diagnostics Market

The New Jersey molecular diagnostics industry is a growing sector with a high growth rate due to its favorable position, with several pharmaceutical and biotechnology companies having a presence there. Several global healthcare companies and research organizations are based in the state, creating a favorable environment for the growth of the molecular diagnostics industry. Molecular diagnostics plays a crucial role in drug development, clinical trials, and detecting diseases, especially cancer and infections. The presence of skilled labor and well-developed lab facilities is an added advantage for the growth of the molecular diagnostics industry. The growing need for personalized medicine and companion diagnostics is also contributing to the growth of the molecular diagnostics industry. Although the high cost of operation and regulatory challenges may act as a challenge for small companies, New Jersey plays a vital role in the growth of the molecular diagnostics industry.

California Molecular Diagnostics Market

The molecular diagnostics market in California is one of the largest and most dynamic in the United States. The state is at the forefront of the biotechnology industry and is known for its innovative spirit. It is home to Silicon Valley, which is known for its technological advances. The high demand for precision medicine, early disease detection, and advanced cancer diagnostics is another major driver for the molecular diagnostics market. It also has a large advantage in terms of investments in research and development, which are encouraged by both sectors. This helps in faster development and application of advanced technology in diagnostic tests. Furthermore, a large population also acts as an advantage because of a greater need for such services. Though challenges still exist in terms of cost and regulatory hurdles, California still plays a major role in defining the future of molecular diagnostics.

Georgia Molecular Diagnostics Market

The molecular diagnostics market in Georgia is witnessing growth due to advancements in healthcare infrastructure and increasing awareness about advanced diagnostic technologies. The country is witnessing growth as a significant emerging market for healthcare services as well as life sciences, particularly in cities like Atlanta. There is a significant increase in the prevalence of chronic as well as infectious diseases, thereby fueling demand for precise as well as timely diagnostic technologies. There is a significant increase in the adoption of molecular diagnostics technologies in hospitals, laboratories, as well as research centers for purposes such as cancer detection as well as infectious disease testing. The initiatives taken by the government to improve healthcare accessibility as well as quality are also contributing to growth. There are also increasing university as well as healthcare collaborations to drive innovation as well as skill development. However, there are certain challenges that are affecting growth. Despite all these challenges, Georgia is gradually strengthening its position in the molecular diagnostics market.

United States Molecular Diagnostics Market Segments

Technology

• Chips and Microarrays
• In Situ Hybridization
• Sequencing
• Mass Spectrometry (MS)
• PCR
• Other Technologies

Application

• Pharmacogenomics
• Infectious Disease
• Genetic Disease Screening
• Oncology
• Blood Screening
• Microbiology
• Human Leukocyte Antigen Typing

Product

• Instruments
• Reagents
• Other Products

End User

• Hospitals
• Laboratories
• Other End Users

States 

1.    California
2.    Texas
3.    New York
4.    Florida
5.    Illinois
6.    Pennsylvania
7.    Ohio
8.    Georgia
9.    New Jersey
10.    Washington
11.    North Carolina
12.    Massachusetts
13.    Virginia
14.    Michigan
15.    Maryland
16.    Colorado
17.    Tennessee
18.    Indiana
19.    Arizona
20.    Minnesota
21.    Wisconsin
22.    Missouri
23.    Connecticut
24.    South Carolina
25.    Oregon
26.    Louisiana
27.    Alabama
28.    Kentucky
29.    Rest of United States

All companies have been covered with 5 Viewpoints

1. Overviews
2. Key Person
3. Recent Developments
4. SWOT Analysis
5. Revenue Analysis

Key Players Analysis

1. F Hoffmann-la Roche Ltd
2. Illumina Ltd
3. Hologic Corporation
4. Agilent Technologies Inc.
5. Qiagen NV
6. Myriad Genetics
7. Abbott Laboratories
8. Danaher Corporation
9. Becton, Dickinson and Company

Report Details: